MedKoo Biosciences/Quizartinib HCl/200072/100mg

RelatedCAS#:1132827-21-4(2HCl) 950769-58-1(freebase)  

Synonym:AC220;AC220;AC-220;AC010220;AC-010220;AC010220;AC010220.2HCl;Quizartinib;QuizartinibHCl;Quizartinibdihydrochloride..

IUPAC/ChemicalName:N-(5-tert-butyl-isoxazol-3-yl)-N"-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}ureadihydrochloride

InChiKey:CVWXJKQAOSCOAB-UHFFFAOYSA-N

InChiCode:InChI=1S/C29H32N6O4S/c1-29(2,3)25-17-26(33-39-25)32-27(36)30-20-6-4-19(5-7-20)22-18-35-23-9-8-21(16-24(23)40-28(35)31-22)38-15-12-34-10-13-37-14-11-34/h4-9,16-18H,10-15H2,1-3H3,(H2,30,32,33,36)

SMILESCode:O=C(NC1=CC=C(C(N=C2SC3=C4)=CN2C3=CC=C4OCCN5CCOCC5)C=C1)NC6=NOC(C(C)(C)C)=C6

TechnicalData

AdditionalInformation

References

1:SmithCC,ZhangC,LinKC,LasaterEA,ZhangY,MassiE,DamonLE,PendletonM,BashirA,SebraR,PerlA,KasarskisA,ShellooeR,TsangG,CariasH,PowellB,BurtonEA,MatusowB,ZhangJ,SpevakW,IbrahimPN,LeMH,HsuHH,HabetsG,WestBL,BollagG,ShahNP.CharacterizingandOverridingtheStructuralMechanismoftheQuizartinib-ResistantFLT3"Gatekeeper"F691LMutationwithPLX3397.CancerDiscov.2015Jun;5(6):668-79.doi:10.1158/2159-8290.CD-15-0060.Epub2015Apr6.PubMedPMID:25847190;PubMedCentralPMCID:PMC4522415.

2:ZornJA,WangQ,FujimuraE,BarrosT,KuriyanJ.CrystalstructureoftheFLT3kinasedomainboundtotheinhibitorQuizartinib(AC220).PLoSOne.2015Apr2;10(4):e0121177.doi:10.1371/journal.pone.0121177.eCollection2015.PubMedPMID:25837374;PubMedCentralPMCID:PMC4383440.

3:AltmanK,SharataH.CatastrophiceruptivekeratoacanthomasandsquamouscellcancersaftertreatmentwithanFLT3inhibitorquizartinib(AC220).DermatolSurg.2015Apr;41(4):530-1.doi:10.1097/DSS.0000000000000316.PubMedPMID:25775444.

4:LevisM.QuizartinibforthetreatmentofFLT3/ITDacutemyeloidleukemia.FutureOncol.2014;10(9):1571-9.doi:10.2217/fon.14.105.Review.PubMedPMID:25145428.

5:WanderSA,LevisMJ,FathiAT.TheevolvingroleofFLT3inhibitorsinacutemyeloidleukemia:quizartinibandbeyond.TherAdvHematol.2014Jun;5(3):65-77.doi:10.1177/2040620714532123.Review.PubMedPMID:24883179;PubMedCentralPMCID:PMC4031904.

6:WolleschakD,MackTS,PernerF,FreyS,SchnöderTM,WagnerMC,HödingC,PilsMC,ParknerA,KlicheS,SchravenB,HebelK,Brunner-WeinzierlM,RanjanS,IsermannB,LipkaDB,FischerT,HeidelFH.ClinicallyrelevantdosesofFLT3-kinaseinhibitorsquizartinibandmidostaurindonotimpairT-cellreactivityandfunction.Haematologica.2014Jun;99(6):e90-3.doi:10.3324/haematol.2014.104331.Epub2014Mar14.PubMedPMID:24633870;PubMedCentralPMCID:PMC4040902.

7:LevisM.Quizartinibinacutemyeloidleukemia.ClinAdvHematolOncol.2013;11(9):586-8.Review.PubMedPMID:24518522.

8:SchaabC,OppermannFS,KlammerM,PfeiferH,TebbeA,OellerichT,KrauterJ,LevisM,PerlAE,DaubH,SteffenB,GodlK,ServeH.GlobalphosphoproteomeanalysisofhumanbonemarrowrevealspredictivephosphorylationMarkersforthetreatmentofacutemyeloidleukemiawithquizartinib.Leukemia.2014Mar;28(3):716-9.doi:10.1038/leu.2013.347.Epub2013Nov19.PubMedPMID:24247654;PubMedCentralPMCID:PMC3948157.

9:OstronoffF,EsteyE.Theroleofquizartinibinthetreatmentofacutemyeloidleukemia.ExpertOpinInvestigDrugs.2013Dec;22(12):1659-69.doi:10.1517/13543784.2013.842973.Epub2013Sep26.Review.PubMedPMID:24070241.

10:CortesJE,KantarjianH,ForanJM,GhirdaladzeD,ZodelavaM,BorthakurG,GammonG,TroneD,ArmstrongRC,JamesJ,LevisM.PhaseIstudyofquizartinibadmiNISTereddailytopatientswithrelapsedorrefractoryacutemyeloidleukemiairrespectiveofFMS-liketyrosinekinase3-internaltandemduplicationstatus.JClinOncol.2013Oct10;31(29):3681-7.doi:10.1200/JCO.2013.48.8783.Epub2013Sep3.PubMedPMID:24002496;PubMedCentralPMCID:PMC3804291.

11:BhullarJ,NatarajanK,ShuklaS,MathiasTJ,SadowskaM,AmbudkarSV,BaerMR.TheFLT3inhibitorquizartinibinhibitsABCG2atpharmacologicallyrelevantconcentrations,withimplicationsforbothchemosensitizationandadversedruginteractions.PLoSOne.2013Aug14;8(8):e71266.doi:10.1371/journal.pone.0071266.eCollection2013.PubMedPMID:23967177;PubMedCentralPMCID:PMC3743865.

12:Kampa-SchittenhelmKM,HeinrichMC,AkmutF,DöhnerH,DöhnerK,SchittenhelmMM.Quizartinib(AC220)isapotentsecondgenerationclassIIItyrosinekinaseinhibitorthatdisplaysadistinctinhibitionprofileagainstmutant-FLT3,-PDGFRAand-KITisoforms.MolCancer.2013Mar7;12:19.doi:10.1186/1476-4598-12-19.PubMedPMID:23497317;PubMedCentralPMCID:PMC3637582.

13:GunawardaneRN,NepomucenoRR,RooksAM,HuntJP,RiconoJM,BelliB,ArmstrongRC.TransientexposuretoquizartinibmediatessustainedinhibitionofFLT3signalingwhilespecificallyinducingapoptosisinFLT3-activatedleukemiacells.MolCancerTher.2013Apr;12(4):438-47.doi:10.1158/1535-7163.MCT-12-0305.Epub2013Feb14.PubMedPMID:23412931.